Onconova Therapeutics (NASDAQ:ONTX)

CAPS Rating: 1 out of 5

Caps

How do you think ONTX will perform against the market?

Add Stock to CAPS Watchlist

All Players

21 Outperform
9 Underperform
 

All-Star Players

7 Outperform
6 Underperform
 

Wall Street

2 Outperform
0 Underperform
 

Top ONTX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.84)
Submitted October 16, 2013

I'm trying to adjust to the new calculus in biopharma, where a market cap of 500M is the bare minimum for a newly public company with an oncology candidate in advanced clinical trials. I'm judiciously adding green thumbs according to that paradigm,… More

zzlangerhans (99.84)
Submitted June 13, 2016

I dropped my coverage of Onconova in early 2014 after the failure of the ONTIME phase III trial of rigosertib monotherapy for MDS. It's not that blown up biotechs can't be interesting or profitable to trade, but that's right about the time I had to… More

ONTX VS S&P 500 (SPY)

ONTX Summary

Recent Community Commentary

Read the most recent pitches from players about ONTX.

Recs

1
Member Avatar zzlangerhans (99.84) Submitted: 6/13/2016 12:19:43 AM : Underperform Start Price: $7.30 ONTX Score: +100.69

I dropped my coverage of Onconova in early 2014 after the failure of the ONTIME phase III trial of rigosertib monotherapy for MDS. It's not that blown up biotechs can't be interesting or profitable to trade, but that's right about the time I had to start paring back my database and Onconova was an obvious candidate for the cut.

A recent price spike drew my attention back to the company, and I was interested in seeing if they had anything new cooking. I found that the stock continued to perform miserably after the 2014 decline and recently underwent a 10:1 reverse split. The market cap is now 19M with 17M of cash as of the end of March, and a burn of 7M last quarter. Meanwhile, Onconova is developing ... rigosertib! The INSPIRE phase III trial of iv rigosertib in higher risk MDA kicked off just six months ago, which means significant catalysts are unlikely for at least the remainder of 2016. Onconova will be presenting some updated data from a phase II trial of oral rigosertib later this month but I think that's unlikely to move the stock significantly. What is far more likely is that Onconova will conduct a large below market dilutive financing that will quash the recent upward momentum, which in turn was likely fomented by promotion and stock manipulation. Between my lack of familiarity with the pipeline and the tiny 3M float, this isn't a short candidate for the time being.

Recs

0
Member Avatar oscillation (75.16) Submitted: 3/7/2015 3:18:23 PM : Outperform Start Price: $22.70 ONTX Score: -117.75

nev

Recs

0
Member Avatar AndrewGreenBull (96.02) Submitted: 2/20/2014 10:06:42 AM : Outperform Start Price: $79.80 ONTX Score: -139.83

When I looked at the data and the cash reserve, I konw ONTX still has a chance. Current price $7.98 is oversold anyway

Leaderboard

Find the members with the highest scoring picks in ONTX.

Score Leader

HeavyDistortion

HeavyDistortion (68.27) Score: +143.78

The Score Leader is the player with the highest score across all their picks in ONTX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
HeavyDistortion 68.27 11/14/2013 Underperform 5Y $122.70 -98.63% +45.15% +143.78 0 Comment
cobradon 96.61 5/8/2014 Underperform 5Y $53.20 -96.84% +38.82% +135.67 0 Comment
IdahoInvestor 29.61 8/17/2015 Underperform 5Y $22.70 -92.60% +24.57% +117.17 0 Comment
cthomas1017 98.72 3/2/2015 Underperform 5Y $22.40 -92.50% +23.35% +115.85 0 Comment
zzlangerhans 99.84 6/10/2016 Underperform 1Y $7.30 -76.99% +23.71% +100.69 1 Comment
stockgripes 99.53 6/10/2016 Underperform 5Y $6.71 -74.96% +23.53% +98.50 0 Comment
warrenout2 72.26 11/14/2016 Underperform 5Y $2.80 -40.00% +19.79% +59.79 0 Comment
thehammer01 95.48 11/30/2016 Underperform 5Y $2.89 -41.87% +17.80% +59.67 0 Comment
warrenout 99.74 11/9/2016 Underperform 5Y $2.37 -29.11% +22.42% +51.54 0 Comment
MBDixieBlue < 20 6/30/2017 Outperform 5Y $2.15 -21.86% +7.49% -29.35 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackPiperJaff 85.10 2/20/2014 Outperform NS $82.80 -97.97% +41.86% -139.83 0 Comment
TrackCitigroup 93.24 10/29/2013 Outperform NS $177.30 -99.05% +47.19% -146.25 0 Comment

Featured Broker Partners